Elvitegravir Quad pill matches efavirenz and atazanavir combos
Protease inhibitor not superior to NNRTI in sub-Saharan Africa
HIV brain impairment: who gets it, and why?
Superinfection: second HIV infections happen as often as first ones
Novel integrase inhibitor dolutegravir still potent at 96 weeks
Controversy regarding strategic treatment interruptions in young children who start ART during infancy
Tenofovir pro-drug GS-7340 shows good safety and efficacy in short study
